Lynparza + Abiraterone approved in the US for the treatment of BRCA mutated mCRPC

US FDA accepts priority review for BMS’s Repotrectinib for treatment of ROS1-positive NSCLC

Precigen received FDA clearance to initiate Phase 2 study of PRGN-2009 in cervical cancer

US FDA approval of Pfizer’s vaccine ABRYSVO for prevention of Respiratory Syncytial Virus